Acalnib (Acalabrutinib) Capsule

Description

Description

This page contains brief details about the drug acalabrutinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Acalabrutinib is an anticancer medicine containing the active constituent acalabrutinib. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. Acalabrutinib was first approved by the U.S. Food and Drug Administration (FDA) on October 31, 2017, to treat adult patients with mantle cell lymphoma who have received at least one prior therapy. It was later approved by the FDA on August 17, 2020, for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Mechanism of Action of Acalabrutinib

The mechanism of acalabrutinib, inhibits the activity of Bruton’s tyrosine kinase (BTK). This protein is essential for the survival and growth of cancer cells in certain types of lymphomas and leukemias. By blocking BTK, it can help to slow down or even stop the growth and spread of cancer cells, which can lead to a reduction in tumor size, an improvement in symptoms, and a delay in disease progression.

Uses of Acalabrutinib

Acalabrutinib is used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). MCL, CLL, and SLL are cancers of the white blood cells called lymphocytes that are part of the immune system.

Acalabrutinib Dosage available

Acalabrutinib is typically administered through injection by a healthcare provider. The specific method of administration may vary depending on the condition being treated and the healthcare provider’s instructions. If a dose is missed, the patient should contact their healthcare provider for further instructions.